The Path Breaking Anti Cancer Vaccine

Promising news seems to be trickling in from many areas in the Europe about the revolutionary new vaccine proficient in arresting cancer. Such reports have borne origin in Prague, Czech Republic, where this effective tool has been produced in the Prague Motor Hospital laboratories for a year, where requests for clinical tests are being drafted.

With no evident side-effects that treatments like chemotherapy pose, this vaccine is effectual in combating a wide array of tumours. Through ten long years of trials and research carried out by Czechs, have finally evolved a distinctive method to develop this vaccine that can be used to treat several ailments like blood cancer, bowel cancer, skin cancer, ovarian cancer and reappearing tumours.

The treatment comes up to 5000 U.S. dollars per person with the effect of the vaccine lastly through the year. The initial prime hitch in using the vaccine being the significant amounts of time required and high-end equipment in super-specialty laboratories utilized in the process of making the vaccine, with the outcome of merely one vaccine in a week, no more than 50 vaccines being developed annually. However, these preliminary hurdles have been eventually overcome with the research touching a level where there is significant production.

Another crucial advance is the premier, globally available, effectual, anti-cancer vaccine OncoVAX(R) to treat colon cancer which first started in Europe. OncoVAX(R) is an effective immunotherapy treatment that has been successful conjugated through years of toiling by several scientists. It successfully averts an array of infective diseases by altering the body’s immune system in such a way that it prevents recurrence of the disease years post surgery and reduces death by more than 50%.

The vaccine, made by scientists, by making use of the tumour found in the body of the patient and giving the patient the vaccine three times a week, a month after the surgery.

BiovaxID, developed by the fruits of labour of Stanford University and the National Cancer Institute, is a personalized remedial vaccine that is effective in exclusively targeting cancerous white blood cells while leaving the healthy cells untouched. BiovaxID is the sole hybrid duo of human white blood cell with cancer cell, the anti-cancer vaccine, which is a high reliability vaccine playing the key role in mounting full blown and absolute attack against the cancer at the same time training the immune system for continued future defence.

The benefits of this miracle vaccine will continue to elude many third world countries for quite sometime, where these vaccines are still not available.

Popularity: 2% [?]